WO2021209441A1 - Utilisation d'un extrait polaire de skeletonema dans une thérapie photodynamique - Google Patents
Utilisation d'un extrait polaire de skeletonema dans une thérapie photodynamique Download PDFInfo
- Publication number
- WO2021209441A1 WO2021209441A1 PCT/EP2021/059545 EP2021059545W WO2021209441A1 WO 2021209441 A1 WO2021209441 A1 WO 2021209441A1 EP 2021059545 W EP2021059545 W EP 2021059545W WO 2021209441 A1 WO2021209441 A1 WO 2021209441A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skeletonema
- extract
- alga
- composition
- genus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Definitions
- the present invention relates to a composition for use in photodynamic therapy (PDT), in particular for treating skin disorders such as acne.
- PDT photodynamic therapy
- the photosensitizer is applied topically to the skin surface. It is then absorbed at the level of the sebaceous gland. The area to be treated is then illuminated by means of a laser or pulsed light, which illumination allows the activation of the photosensitizer and the genesis of singlet oxygen and ROS.
- singlet oxygen which constitutes a hyper-reactive chemical species, causes the death of bacteria proliferating in pores of the skin and localized peeling of the skin to free the clogged pores.
- the photosensitizer when not activated in the absence of photostimulation, must be stable in vivo and exhibit strong photoreactivity after illumination.
- the photosensitizer preserves the skin cells as much as possible and does not increase the inflammation resulting from acne.
- a first subject relates to a composition for photodynamic treatment (PDT) comprising at least a polar extract of an alga of the genus Skeletonema or a photosensitizer derived therefrom.
- this composition is a dermatological composition.
- this composition can also aim to prevent and / or treat acne in a subject by the topical application of the composition to a skin surface of the subject in combination with a light exposure of this skin surface so to allow activation of the photosensitizer.
- this composition can be aimed at preventing and / or treating a bacterial infection in a subject by the topical application of the composition to a surface. epithelium of the subject in combination with a light exposure of this epithelium surface so as to allow activation of the photosensitizer.
- a second subject relates to a method of photodynamic treatment which comprises the steps of: [18] 1) topical application to an epithelium surface of a subject of a therapeutically effective amount of a composition as described above ; and
- the photodynamic treatment aims to prevent and / or treat acne in a subject.
- the photodynamic treatment aims to prevent and / or treat a bacterial infection in a subject.
- a third object of the invention relates to a cosmetic treatment process with a view to eliminating skin imperfections such as comedones and / or blackheads comprising the steps of:
- a fourth object of the invention relates to a kit for photodynamic treatment, which comprises:
- a fifth object of the invention relates to a process for decontaminating a surface, which process comprises at least the steps of:
- the surface to be decontaminated is a surface of medical devices, prostheses or implants.
- this process is used in the food industry and the surface to be decontaminated is a food surface (meat, fish, etc.), a metal surface.
- a sixth object of the invention relates to a method of photo-coagulation of a wound of a subject, which method comprises at least the steps of:
- Algae of the genus Skeletonema are unicellular algae which are also diatoms (Bacillariophyta).
- the alga of the genus Skeletonema is chosen from the group comprising Skeletonema costatum, Skeletonema grethae, Skeletonema marinoi,
- the alga of the genus Skeletonema corresponds to Skeletonema marino ⁇ or Skeletonema grethae, and more specifically to Skeletonema marinoi which is a relatively common species in the Atlantic (it is often the major species of coastal waters in the Atlantic).
- the cells of this species remain attached to each other after cell divisions.
- the algae of this species are in the form of chains of 3 to 15 cells.
- the term “polar extract of an alga of the genus Skeletonema” refers to a composition obtained by an extraction carried out on an alga of the genus Skeletonema with a polar solvent.
- polar solvent is understood to mean a solvent consisting of molecules exhibiting a dipole moment. This polar solvent can be practical or aprotic depending on whether or not it is capable of releasing acidic H + ions.
- ketones eg acetone or butanone
- sulfoxides eg DMSO
- N, N disubstituted amides N, N dimethyl formamide
- nitriles eg acetonitrile
- esters eg ethyl acetate
- tertiary amines eg triethylamine
- nitrogenous heterocycles eg pyridine
- Examples of a practical polar solvent include water, alcohols, carboxylic acids (eg, formic acid and acetic acid) or primary and secondary amines.
- the polar solvent used will be a practical polar solvent, and among them, an alcohol is preferred.
- the polar extract of an alga of the Skeletonema genus used will preferably be a polar extract obtained from a microalga which has undergone a prior cell lysis step.
- Such a cell lysis step can be carried out simply by freezing / thawing (preferably at a temperature below -20 ° C.), by microwave treatment or by ultrasonic treatment of this alga.
- the polar extract of an alga of the genus Skeletonema results from a maceration of this alga in the polar solvent for a period of at least 5 minutes, preferably at least 10 minutes. Typically, this maceration time is less than 24 hours, preferably less than 12, or even less than 6 hours.
- such a polar extract of the alga of the Skeletonema genus will be obtained by maceration of this alga in the polar solvent for a period of between 10 and 60 minutes, preferably between 20 and 40 minutes.
- this polar extract of an alga of the Skeletonema genus it always results from an extraction using at least 1 ml of polar solvent per gram of microalga (expressed in dry weight), preferably at least 10 mL of polar solvent per gram of microalga and, particularly preferably at least 20 mL of polar solvent per gram of microalga.
- the polar extract of an alga of the Skeletonema genus is obtained by using between 1 and 200 ml of polar solvent per gram of microalga (expressed in dry weight), preferably between 10 and 100 ml of polar solvent per gram of microalga and, particularly preferably between 20 and 50 mL of polar solvent per gram of microalga (expressed in dry weight).
- the polar extract of an alga of the Skeletonema genus will have undergone at least one filtration (eg 0.2 ⁇ m, 0.4 ⁇ m or other filter) and / or at least one centrifugation (with recovery of the sole supernatant. ) following extraction.
- photosensitizer derived from a polar extract of an alga of the genus Skeletonema one refers to a compound purified from a polar extract of an alga of the genus Skeletonema (for example by HPLC) or to a compound present in a polar extract of an alga of the genus Skeletonema which, when activated by light, allows the production of singlet oxygen and ROS
- the content of extract of an alga of the Skeletonema genus in the composition for a photodynamic treatment is between 0.001% and 5% (by dry weight of extract relative to the total weight of the composition), preferably between 0 , 01% and 2% and, particularly preferably between 0.1% and 1%.
- the integration of the polar extract will preferably take place under an inert atmosphere (eg nitrogen or argon) and / or in the dark.
- an inert atmosphere eg nitrogen or argon
- Such integration conditions make it possible to best protect the active molecules of the extract.
- the composition is preferably applied to an epithelial surface such as the skin.
- a dermatological composition such as an ointment, a cream, a lotion or even a gel.
- the composition may further comprise at least one antioxidant.
- an antioxidant agent which can be used in such a composition, mention may be made of provitamins A, vitamin C, vitamin E, polyphenols or even lycopene. We will preferably opt for a provitamin A, vitamin C or vitamin E.
- this composition may comprise many types of adjuvants or active ingredients used in pharmaceutical or cosmetic formulations, preferably dermatological, whether they are fatty substances, organic solvents, or '' thickeners, gelling agents, softeners, antioxidants, opacifiers, stabilizers, foaming surfactants and / or detergents, emollients, superfatters, perfumes, ionic or non-ionic emulsifiers, fillers, sequestering agents, chelators, preservatives, essential oils, coloring matters, pigments, hydrophilic or lipophilic active ingredients, humectants, such as for example glycerin or glycols, preservatives, dyes, cosmetic active ingredients , mineral and / or organic sunscreens, mineral fillers, synthetic fillers, silicone elastomers, or plant extracts or even lipid vesicles, or any other ingredient usually used in cosmetic.
- adjuvants or active ingredients used in pharmaceutical or cosmetic formulations, preferably dermatological, whether they are fatty substances
- oils we can cite paraffins, isoparaffins, white mineral oils, vegetable oils (from flowers, fruits, vegetables, trees, cereals, oilseeds ... ), animal oils, synthetic oils, silicone oils and fluorinated oils; and more particularly: oils of vegetable origin, such as sweet almond oil, coconut oil, castor oil, jojoba oil, olive oil, coconut oil, rapeseed, peanut oil, sunflower oil, wheat germ oil, corn germ oil, soybean oil, cottonseed oil, alfalfa oil, l poppy oil, pumpkin oil, evening primrose oil, millet oil, barley oil, rye oil, safflower oil, sayoulier oil, l passionflower oil, hazelnut oil, palm oil, shea butter, apricot kernel oil, calophyllum oil, sisymbre oil, avocado oil , calendula oil, oils obtained from flowers or vegetables; ethoxylated vegetable oils; oils of animal origin, such as squalene, squalane
- dimethylpolysiloxanes methylphenylpolysiloxanes
- silicones modified with amines silicones modified with fatty acids
- silicones modified with alcohols silicones modified with alcohols and fatty acids
- silicones modified. with polyether groups silicones modified with epoxy modified silicones
- silicones modified with fluorinated groups silicones modified with cyclic silicones and silicones modified with alkyl groups.
- fatty alcohols linear or branched, saturated or unsaturated, mixtures of fatty alcohols, linear and / or branched, saturated and / or unsaturated, or fatty acids, linear or branched , saturated or unsaturated, mixtures of linear or branched fatty acids, saturated or unsaturated.
- thickening and / or emulsifying polymers which can be used, there are, for example, homopolymers or copolymers of acrylic acid or of derivatives of acrylic acid, homopolymers or copolymers of methacrylic acid or derivatives of acrylic acid.
- emulsifying surfactants chosen from alkylpolyglycosides; [68] - associations of alkylpolyglycosides and fatty alcohols, esters of polyglycerols or of polyglycols or of polyols. [69] Among the surfactants which can be used in the compositions according to the invention, there may be mentioned: the topically acceptable anionic, cationic, amphoteric or nonionic surfactants usually used in this field of activity.
- anionic surfactants which can be used in the compositions according to the invention, particular mention will be made of alkali metal salts, alkaline earth metal salts, ammonium salts, amino acid salts, salts of. aminoalcohols of the following compounds: alkylethersulphates, alkylphosphates, alkylamidoethersulphates, alkylarylpolyethersulphates, monoglycerides sulphates, alpha-olefin sulphonates, paraffin sulphonates, alkylphosphates, alkylamidoethersulphates, alkylsulphonates, alkyl arylsulphonates, alkylaryl sulphonates, alkylaryl sulfonates alkylsulfosuccinates, alkylethersulfosuccinates, alkylamidesulfosuccinates, alkylsulfoacetates, alkylsarcosinates, acyl
- amphoteric surfactants that can be used in the compositions according to the invention, mention may be made of alkylbetaines, alkylamidobetaines, sultaines, alkylamidoalkylsulfobetaines, imidazoline derivatives, phosphobetaines, amphopolyacetates and amphopropionates.
- the latter may be combined with other active agents, in particular those known for their anti-aging, firming, restructuring, stimulating, energizing, anti-aging action. wrinkle, relaxant, moisturizer, antimicrobial, sebum regulator, purifying, soothing, relaxing, relaxing, anti-stress, brightening, immunomodulator, stimulator of cell renewal, lifting, plumping, improving the radiance of the complexion, etc.
- the light exposure of the area to be treated allowing the activation of the photosensitizer present in this extract is an exposure to a light wave having a wavelength between 400 and 800 nm, preferably between 450 and 700 nm, and an intensity (fluence) of between lJ / cm 2 and 100 J / cm 2 , preferably between 1 and 10 J / cm 2 .
- Such a light wave can be obtained by means of a laser, pulsed light, or even LEDs.
- the use of LEDs will be preferred with regard to the absence of heating undergone by the cells of the subject so as to limit the damage undergone by his dermis and his skin. epidermis. Now, such a light wave could possibly also correspond to daylight.
- the exposure time will be between 1 minute and 2 hours, preferably between 1 and 30 minutes, see between 1 and 10 minutes and, particularly preferably between 2 and 5 minutes.
- photodynamic treatment is meant a treatment by light exposure of the composition, after its application, so as to allow the activation of the photosensitizer present in the polar extract of an alga of the genus Skeletonema.
- photodynamic treatments are possible such as for example the treatment of acne, the treatment of bacterial infections of the skin or the gum, the treatment of hirsutism by the destruction of follicles, the treatment of baldness by stimulation of the scalp in areas of hair loss, treatment of inflammatory keratosis, treatment of pre-melanoma skin areas, treatment of psoriasis, treatment of benign skin conditions such as wine stains, warts , the treatment of the various forms of hydrosadenitis such as suppurative hydradenitis, Vemeuil's disease, or else an antiangiogenic treatment, in particular that of the rosette.
- the dermatological composition is aimed at the treatment of acne in a subject by the topical application of the composition to a skin surface of the subject in combination with a light exposure of this skin surface so as to allow the activation of the photosensitizer present in the extract.
- this one can correspond just as well to vulgar acne, to polymorphic acne, to nodulocystic acne, to acne conglobata as to secondary acne (ex. solar acne or acne associated with treatment).
- the composition according to the invention aims to prevent and / or treat the hypersecretion of sebum by the sebaceous glands.
- the composition according to the invention can also be aimed at preventing and / or treating a bacterial infection in a subject by topical application of the composition to an epithelium surface of the subject in combination with exposure. luminous surface of this epithelium surface so as to allow activation of the photosensitizer present in the extract.
- the bacterial infection is an infection of Gram positive bacteria.
- the epithelium surface on which the dermatological composition is applied may correspond to the gum (gingivitis or periodontitis) or to a skin surface, such as the face, trunk, legs, back or fingers, of preferably to the face.
- Subject matter is a mammal, preferably a human.
- the subject will typically be between 10 and 20 years of age. Now, the onset of acne can be around 7-8 years old and persist after 20 years, the subject may be younger than 10 years and older than 20 years.
- composition according to the invention is applied to the affected epithelium surface (skin, gum, etc.) at least once a day.
- the photodynamic treatment corresponds to one of the treatments considered previously.
- the method according to the invention aims to prevent and / or treat acne in a subject.
- the method according to the invention aims to prevent and / or treat a bacterial infection in a subject.
- terapéuticaally effective amount is meant an amount sufficient to achieve the desired biological effect.
- this aims to eliminate comedones and / or blackheads.
- kit according to the invention comprises, in addition to the composition as described above, a light source capable of inducing the activation of the photosensitizer present in the algae extract
- such a light source emits light radiation having a wavelength between 400 and 800 nm, preferably between 450 and 700 nm, with an intensity (fluence) between lJ / cm 2 and 100 J / cm 2 , preferably between 1 and 10 J / cm 2 [100]
- a light source is typically chosen from a laser, pulsed light, or even an LED, preferably between pulsed light and an LED.
- a formulation of the extract allowing its vaporization on the surface to be decontaminated.
- a spray type formulation constitutes a particularly suitable formulation.
- Example 1 Obtaining a polar extract from an alga of the genus Skeletonema:
- the entire extraction is carried out under an inert atmosphere (nitrogen saturation) in order to avoid pronounced degradation of the active molecules.
- an inert atmosphere nitrogen saturation
- the algae are frozen at -20 ° C. before being immersed in 400 ml of ethanol with stirring at room temperature for at least one hour (typically 4 hours).
- the extract is then centrifuged to remove the pellet containing silica in particular, then the supernatant is filtered (eg 0.2 ⁇ m filter).
- Example 2 Antibacterial action of a polar extract of an alga of the genus Skeletonema: [114] The antibacterial activity of the polar extract S. marino ⁇ obtained is evaluated by means of an agar diffusion test. on the following strains: Cutibacterium acnes (CIP 53.117T), Staphylococcus aureus (CIP 76.25), Staphylococcus epidermidis (CIP 109.562).
- the Petri dishes are subjected or not to illumination with light sources delivering either white light (total fluence 25 J / cm 2 ) or red light (total fluence 37.5 J / cm 2 ).
- a no-illumination condition is performed to determine whether the extract has antibacterial activity (toxicity) or not, in the absence of illumination.
- the MIC and the CMB of the polar extracts S. marino ⁇ , S. grethae, S. subsalsum and S. menzelii were determined by a micromethod in 96 well plate.
- the MIC (Minimum Inhibition Concentration) of an extract corresponds to the smallest concentration of polar extract sufficient to inhibit the growth of a bacterial strain.
- the CMB (Minimum Bactericidal Concentration) of the extract corresponds to the smallest concentration of extract sufficient to kill 99.99% of the bacteria of the initial inoculum.
- Bacteria C. acnes, S. aureus, S. epidermidis
- phase exponential growth are incubated in the presence of different concentrations of a polar extract.
- the bacteria in the presence of the polar extract are then subjected to illumination, either white light (total fluence 25 J / cm 2 ) or red light (total fluence 37.5 J / cm 2 ).
- illumination either white light (total fluence 25 J / cm 2 ) or red light (total fluence 37.5 J / cm 2 ).
- a no-illumination condition is performed to determine whether the tested polar extract has antibacterial activity (toxicity) or not, in the absence of illumination (darkness).
- the 96-well plates are then incubated in an oven while respecting the optimal conditions for the growth of bacteria.
- Example 4 In vitro evaluation of the anti-inflammatory effect of the extract of polar algae S. marino ⁇
- NHEK human epidermal keratinocytes were inoculated in K-SFM medium supplemented with 0.25 ng / mL of EGF (Epidermal Growth Factor), 25 pg / mL of pituitary extract and 25 pg / mL of Gentamycin in a 96-well plate and then incubated at 37 ° C under an atmosphere containing 5% CO2. After at least one day of cultivation, the NHEK cells are preincubated for 24 hours in the presence or in the absence of different concentrations of the polar extract S. marino ⁇ . As a positive control for anti-inflammatory activity, NHEK cells were also preincubated in the presence of bafilomycin (100 nM).
- EGF Epidermal keratinocytes
- Example 5 In vitro evaluation of the anti-lipogenic effect of the extract of polar alga S. marino ⁇ [152] 5.1 Method
- the SEB0662AR cells are incubated in the presence of cerulenin. At the end of the incubation period, the total lipids are fluorescently labeled and the inhibition of lipogenesis is determined for each condition.
- the extract of the polar algae S. marino ⁇ has no effect on the viability of the cells. Indeed, counting the number of nuclei per field indicates a globally comparable number of nuclei for all the conditions tested. In addition, no morphological alteration could be observed during microscopic observations made at the end of incubation. As a result, the inhibitory effect of the S. marino ⁇ polar algae extract on lipogenesis is specific and not linked to an associated partial cytotoxicity phenomenon.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022020932A BR112022020932A2 (pt) | 2020-04-14 | 2021-04-13 | Composição dermatológica para tratamento fotodinâmico (pdt), método cosmético para remoção de cravos pretos e kit destinado ao tratamento fotodinâmico |
JP2022560986A JP2023529257A (ja) | 2020-04-14 | 2021-04-13 | 光線力学療法におけるスケレトネマ(Skeletonema)の極性抽出物の使用 |
KR1020227039445A KR20230002645A (ko) | 2020-04-14 | 2021-04-13 | 광역학 치료에서 스켈레토네마 극성 추출물의 용도 |
EP21716792.3A EP4135768A1 (fr) | 2020-04-14 | 2021-04-13 | <smallcaps/>? ? ?skeletonema? ? ? ? ?utilisation d'un extrait polaire dedans une thérapie photodynamique |
US17/918,751 US20230241142A1 (en) | 2020-04-14 | 2021-04-13 | Use of a polar extract of skeletonema in photodynamic therapy |
CN202180028034.XA CN115379857A (zh) | 2020-04-14 | 2021-04-13 | 骨条藻属的极性提取物在光动力疗法中的使用 |
ZA2022/10407A ZA202210407B (en) | 2020-04-14 | 2022-09-20 | Use of a polar extract of skeletonema in photodynamic therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2003712 | 2020-04-14 | ||
FR2003712A FR3109086A1 (fr) | 2020-04-14 | 2020-04-14 | utilisation d’un extrait polaire de Skeletonema dans une thérapie photodynamique |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021209441A1 true WO2021209441A1 (fr) | 2021-10-21 |
Family
ID=72709416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/059545 WO2021209441A1 (fr) | 2020-04-14 | 2021-04-13 | Utilisation d'un extrait polaire de skeletonema dans une thérapie photodynamique |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230241142A1 (fr) |
EP (1) | EP4135768A1 (fr) |
JP (1) | JP2023529257A (fr) |
KR (1) | KR20230002645A (fr) |
CN (1) | CN115379857A (fr) |
BR (1) | BR112022020932A2 (fr) |
FR (2) | FR3109086A1 (fr) |
WO (1) | WO2021209441A1 (fr) |
ZA (1) | ZA202210407B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024057032A1 (fr) * | 2022-09-14 | 2024-03-21 | I-Smart Developments Limited | Système et méthode de traitement cutané |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000013660A1 (fr) * | 1998-09-09 | 2000-03-16 | Parfums Christian Dior | Extrait lipidique de l'algue skeletonema |
FR2791568A1 (fr) * | 1999-04-02 | 2000-10-06 | Lvmh Rech | Composition cosmetique comprenant au moins une subtance favorisant la formation de connexine, utilisation et procede de traitement cosmetique |
EP1755676B1 (fr) | 2004-06-09 | 2012-11-28 | QLT, Inc. | Thérapie photodynamique pour le traitement d'affections des glandes sébacées hyperactives en utilisant verteporfin et/ou lemuteporfin |
EP2152259B1 (fr) | 2007-05-04 | 2013-07-31 | Galderma Research & Development | Utilisation d'un dérivé d'acide naphtoïque combinée à une lumière rouge et/ou bleue dans le traitement d'acné vulgaire |
EP3082788B1 (fr) | 2013-12-20 | 2018-11-21 | Galderma Research & Development | Traitement d'acne par la therapie photodynamique a impulsions |
-
2020
- 2020-04-14 FR FR2003712A patent/FR3109086A1/fr active Pending
-
2021
- 2021-04-13 EP EP21716792.3A patent/EP4135768A1/fr active Pending
- 2021-04-13 WO PCT/EP2021/059545 patent/WO2021209441A1/fr unknown
- 2021-04-13 BR BR112022020932A patent/BR112022020932A2/pt unknown
- 2021-04-13 JP JP2022560986A patent/JP2023529257A/ja active Pending
- 2021-04-13 KR KR1020227039445A patent/KR20230002645A/ko active Search and Examination
- 2021-04-13 US US17/918,751 patent/US20230241142A1/en active Pending
- 2021-04-13 CN CN202180028034.XA patent/CN115379857A/zh active Pending
-
2022
- 2022-09-20 ZA ZA2022/10407A patent/ZA202210407B/en unknown
-
2023
- 2023-05-30 FR FR2305321A patent/FR3135893A1/fr active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000013660A1 (fr) * | 1998-09-09 | 2000-03-16 | Parfums Christian Dior | Extrait lipidique de l'algue skeletonema |
FR2791568A1 (fr) * | 1999-04-02 | 2000-10-06 | Lvmh Rech | Composition cosmetique comprenant au moins une subtance favorisant la formation de connexine, utilisation et procede de traitement cosmetique |
EP1755676B1 (fr) | 2004-06-09 | 2012-11-28 | QLT, Inc. | Thérapie photodynamique pour le traitement d'affections des glandes sébacées hyperactives en utilisant verteporfin et/ou lemuteporfin |
EP2152259B1 (fr) | 2007-05-04 | 2013-07-31 | Galderma Research & Development | Utilisation d'un dérivé d'acide naphtoïque combinée à une lumière rouge et/ou bleue dans le traitement d'acné vulgaire |
EP3082788B1 (fr) | 2013-12-20 | 2018-11-21 | Galderma Research & Development | Traitement d'acne par la therapie photodynamique a impulsions |
Non-Patent Citations (4)
Title |
---|
M NAVINER ET AL: "Antibacterial activity of the marine diatom Skeletonema costatum against aquacultural pathogens", AQUACULTURE, vol. 174, no. 1-2, April 1999 (1999-04-01), pages 15 - 24, XP055751553, ISSN: 0044-8486, DOI: 10.1016/S0044-8486(98)00513-4 * |
OSCAR GONZÁLEZ-DAVIS ET AL: "Bioprospection of Microalgae and Cyanobacteria as Biocontrol Agents Against Vibrio campbellii and Their Use in White Shrimp Litopenaeus vannamei Culture", JOURNAL OF THE WORLD AQUACULTURE SOCIETY, vol. 43, no. 3, June 2012 (2012-06-01), pages 387 - 399, XP055751558, ISSN: 0893-8849, DOI: 10.1111/j.1749-7345.2012.00567.x * |
SUSHANTH V R ET AL: "Antioxidant and antimicrobial activities in the four species of marine microalgae isolated from Arabian Sea of Karnataka Coast", vol. 44, no. 1, 31 December 2014 (2014-12-31), pages 69 - 75, XP009524124, ISSN: 0379-5136, Retrieved from the Internet <URL:http://nopr.niscair.res.in/bitstream/123456789/34627/1/IJMS%2044%281%29%2069-75.pdf> * |
TEREKHOVA V E ET AL: "Influence of extrametabolites of marine microalgae on reproduction of the bacterium Listeria monocytogenes", vol. 35, no. 4, 30 June 2009 (2009-06-30), pages 306 - 309, XP009524123, ISSN: 0134-3475, Retrieved from the Internet <URL:https://link.springer.com/article/10.1134/S1063074009040129> DOI: 10.1134/S1063074009040129 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024057032A1 (fr) * | 2022-09-14 | 2024-03-21 | I-Smart Developments Limited | Système et méthode de traitement cutané |
Also Published As
Publication number | Publication date |
---|---|
ZA202210407B (en) | 2023-05-31 |
US20230241142A1 (en) | 2023-08-03 |
BR112022020932A2 (pt) | 2023-03-14 |
FR3135893A1 (fr) | 2023-12-01 |
CN115379857A (zh) | 2022-11-22 |
KR20230002645A (ko) | 2023-01-05 |
FR3109086A1 (fr) | 2021-10-15 |
JP2023529257A (ja) | 2023-07-10 |
EP4135768A1 (fr) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1786384A1 (fr) | Utilisation d'au moins un triene d'acide gras conjugue pour la preparation d'un medicament destine au traitement de l'inflammation | |
EP3113850B1 (fr) | Composition cosmetique eclaircissante | |
WO2012085230A1 (fr) | Extrait de parties aeriennes de gynandropsis gynandra ou cleome gynandra et compositions cosmetiques, dermatologiques ou pharmaceutiques le comprenant | |
FR3135893A1 (fr) | utilisation d’un extrait polaire de Skeletonema dans une thérapie photodynamique | |
EP3102181A1 (fr) | Complexe actif pour un produit cosmétique contre le vieillissement cutané | |
EP3980124B1 (fr) | Extrait du tourteau des graines de moringa peregrina, son procédé d'obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques | |
WO2020008151A1 (fr) | Composition huileuse contenant un extrait de mimosa tenuiflora et utilisations | |
EP3980123B1 (fr) | Extrait de graines de moringa peregrina riche en 2,5-diformylfuran, son procédé d'obtention et son utilisation dans des compositions cosmétiques | |
EP3052198B1 (fr) | Composition huileuse contenant un extrait d'hemerocalle et utilisations | |
FR3061013A1 (fr) | Composition contenant le digeneaside, son procede d'obtention et son utilisation cosmetique, veterinaire ou nutraceutique | |
WO2009138583A2 (fr) | Utilisation d'une composition contenant de l'ergosterol ou un extrait naturel de micro-organisme ou vegetal ou animal | |
FR2811893A1 (fr) | Utilisation d'au moins un extrait d'au moins une iridacee dans une composition destinee a stimuler defenses immunitaires | |
EP2811978B1 (fr) | Utilisation d'un extrait d'ecorce de pommier dans une composition cosmetique anti-age | |
OA21067A (fr) | Extrait de graines de Moringa Peregrina riche en 2,5-diformylfuran, son procédé d'obtention et son utilisation dans des compositions cosmétiques. | |
FR3021539A1 (fr) | Composition cosmetique et/ou dermatologique comprenant un extrait vegetal et un activateur de genes | |
EP3052201B1 (fr) | Utilisation d'une composition huileuse contenant un extrait d'hemerocalle pour ameliorer l'eclat du teint | |
FR2986708A1 (fr) | Composition a base d'extrait de feuille de pommier pour le raffermissement de la peau | |
OA21068A (fr) | Extrait du tourteau des graines de Moringa Peregrina, son procédé d'obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques. | |
FR3003170A1 (fr) | Utilisation d'un extrait de jacinthe d'eau pour l'hydratation de la peau | |
FR3110419A1 (fr) | Extrait de graines de Moringa peregrina riche en 2,5-diformylfuran, son procédé d’obtention et son utilisation dans des compositions cosmétiques | |
WO2012136930A2 (fr) | Composition a base d'huile de chaulmoogra et de tribulus terrestris pour la pigmentation de la peau | |
FR2986707A1 (fr) | Composition comprenant un extrait de jus de pomme pour le confort cutane. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21716792 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022560986 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022020932 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227039445 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021716792 Country of ref document: EP Effective date: 20221114 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112022020932 Country of ref document: BR Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, DOCUMENTOS COMPROBATORIOS QUE EXPLIQUEM E REGULARIZEM A DIVERGENCIA NOS NOMES DOS DEPOSITANTES CONSTANTES NA PUBLICACAO INTERNACIONAL WO/2021/209441 DE 21/10/2021 COMO INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER) E CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES OS CONSTANTES NAS PETICOES COMO IFREMER E CHU NANTES UMA VEZ QUE NAO HOUVE ENVIO DE DOCUMENTO COMPROVANDO QUE O NOME CORRETO DOS DEPOSITANTES E O DECLARADO NA ENTRADA NACIONAL. |
|
ENP | Entry into the national phase |
Ref document number: 112022020932 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221014 |